Stock comparison
Eton Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ETON
Eton Pharmaceuticals
Market cap
$892.72M
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ETON | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 17F | 69B | MTD |
| Benjamin Graham | 44D | 65B | MTD |
| Philip Fisher | 40D | 63C | MTD |
| Peter Lynch | 46D | 66B | MTD |
| Joel Greenblatt | 0F | 68B | MTD |
| Charlie Munger | 22F | 74B | MTD |
| Terry Smith | 22F | 70B | MTD |
Side-by-side metrics
| Metric | ETON | MTD |
|---|---|---|
| Market cap | $892.72M | $22.29B |
| P/E (TTM) | - | 25.3x |
| EV/EBIT | 11026.8x | 21.6x |
| ROIC (TTM) | -1.35% | 36.09% |
| Gross margin | 53.46% | 57.79% |
| Net margin | -5.75% | 21.4% |
| Revenue CAGR 5y | 38.33% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 0.4x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ETON leads on
- P/E (TTM)-vs 25.3x+115%
- Revenue CAGR 5y38.33%vs 2.01%+95%
MTD leads on
- Net margin21.4%vs -5.75%+127%
- ROIC (TTM)36.09%vs -1.35%+104%
- Debt / Equity-vs 0.4x+101%
- EV/EBIT21.6xvs 11026.8x+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.